Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to lead design and provide engineering services, procurement and construction support for Pfizer, Inc.'s new $350 million Global Biotechnology Center investment in the Hangzhou Economic Development Area in China.

Under the terms of the agreement, Jacobs is responsible for developing the overall site design, which includes aseptic fill/finish, drug substance and central utility buildings; a quality laboratory; administration offices; and a warehouse. The facility is being built to produce monoclonal antibodies and also serve as a process development and clinical supply site for biologic medicines in China.

In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, "This is an exciting opportunity for our Life Sciences business. We have a long history of helping Pfizer grow and expand its global manufacturing capabilities. We look forward to partnering with Pfizer once again to develop this state-of-the-art biotechnology center in China."

The facility is expected to be complete in 2018.

Jacobs is one of the world's largest and most diverse providers of full-spectrum technical, professional and construction services for industrial, commercial and government organizations globally. The company employs 50,000 people and operates in more than 30 countries around the world. Jacobs' Life Sciences business is the largest professional services provider to the pharmaceutical and biotechnology industries. For more information, visit www.jacobs.com.

Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2015 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160823005110/en/

Copyright Business Wire 2010